October 3rd 2023
Exkivity remains available while Takeda works with the FDA on withdrawal timing, and the company said that patients currently taking the therapy will continue to have access after it is withdrawn.
September 28th 2023
ROS1-Targeted Treatments in NSCLC: Updates and Best Practices for Managed Care
1.5 Credit(s) / Oncology
View More
Chronic Myeloid Leukemia: Navigating Drug Resistance and Optimizing Care
View More
Developing Clinical Pathways for Treatment of Advanced/Metastatic ccRCC in Managed Care Pharmacy: Opportunities, Challenges, and Best Practices
1.5 Credits / Oncology
View More
Investigating the Optimal Use of Novel Immunotherapies for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
1.5 / Oncology, Hematology
View More
Clinical Conversations With the Cancer Care Team: Discussing the Impact of Social Inequities on Treatment Outcomes in Triple-Negative Breast Cancer
1.5 Credits / Oncology, Women's Health
View More
Optimizing Care of Patients on Immune Checkpoint Inhibitors: An Oncology Primer for Community Pharmacists
1.25 Credits / Oncology
View More
Updates on the Utility of PARP Inhibitors in the Treatment of Ovarian Cancer: Opportunities for Pharmacists to Improve Patient Care
0.75 Credit / Oncology, Women's Health
View More
Oral Chemotherapy Parity Legislation: Opportunities for Cancer Care Equity
1.0 Credit / Law, Oncology
View More
Exploring the Evolving Treatment Landscape for Patients With Waldenström Macroglobulinemia
0.75 Credit / Oncology
View More
Advances in the Use of Immune Checkpoint Inhibitors to Treat Non-Melanoma Skin Cancers: Updates for Oncology Pharmacists
0.75 Credit / Oncology
View More
Acute Myeloid Leukemia: Novel Targeted Therapies and the Role of the Pharmacist
0.75 Credit / Oncology
View More
The Role of Immune Checkpoint Inhibitors in Cutaneous Melanoma: Evaluating Therapeutic Trends
0.75 Credit / Oncology
View More
Advances in Prostate Cancer: An Evidence-based Review for Managed Care Professionals
1.0 Credit / Oncology, Urology
View More
ESMO Congress 2022: Advances and Best Practices for Managed Care Pharmacists in the Treatment of Metastatic Head and Neck Squamous cell Carcinoma
1.0 Credit / Oncology
View More
Making the Most of Anti-Androgen Therapies in Prostate Cancer Through Pharmacist Interventions
1.25 Credits / Oncology
View More
Advances in High-Risk Myelodysplastic Syndromes: Insights and Application for Managed Care With ASH Annual Meeting Coverage
1.0 Credit / Hematology, Oncology
View More
A Pharmacist’s Guide to the Use of Targeted Therapy for HER2-Positive Breast Cancer
1.5 Credits / Oncology, Women's Health
View More
Managed Care Considerations and Implementation Strategies for Biosimilars in Oncology
1.0 Credit / Biosimilars, Oncology
View More
Exploring the Emerging Treatment Landscape of Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Focus on Novel Immunotherapies
1.5 Credits / Hematology, Oncology
View More
Advances in the Treatment of Non-Melanoma Skin Cancers: The Role of Immune Checkpoint Inhibitors
1.5 Credits / Dermatology, Oncology
View More
Continuing the Conversation: Exploring the Emerging Treatment Landscape of Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Focus on Novel Immunotherapies
0.5 Credit / Hematology, Oncology
View More
Exploring New and Emerging Oral Treatments in HR-Positive, HER2-Negative Breast Cancer: A Primer for Health-System Pharmacists
1.5 Credits / Breast Cancer, Oncology, Women's Health
View More
Tumor-Infiltrating Lymphocytes: Infiltrating the Boundaries of Cancer Care in Solid Tumors Through a Managed Care Lens
1.0 Credit / Oncology
View More
Updates in the Treatment of Steroid-Refractory Chronic Graft-versus-Host Disease and the Role of the Oncology Pharmacist
1.5 Credits / Oncology
View More
Oncology Pharmacists Connect: Winter 2024
View More
Prostate Cancer: Insights and Application for Managed Care from ASCO 2022
1.0 Credit / Oncology, Urology
View More
Updates in the Targeted Treatment and Management of Unresectable or Metastatic Cholangiocarcinoma for Managed Care Pharmacists
1.0 Credit / Oncology, Rare Diseases
View More
Managed Care Insights on Optimizing the Use of BCMA-Targeted Treatments in Multiple Myeloma
1.5 Credits / Hematology, Oncology
View More
The Evolving Treatment Landscape for HR+/HER2- Breast Cancer: Updates and Considerations for Managed Care
1.5 Credits / Oncology, Women's Health
View More
Exploring Clinical Updates in HR+/HER2- Breast Cancer Treatment and the Impact on Patient Care
1.0 Credit / Oncology, Women’s Health
View More
High BMI in Breast Cancer Patients Linked With Increased Cardiotoxicity During Chemotherapy
August 9th 2023A recent study being presented at the American College of Cardiology Latin America 2023 conference found the prevalence of cardiotoxicity among patients with breast cancer undergoing chemotherapy was 11.94%.